Statins as Potential Therapeutics for Lung Cancer Molecular Mechanisms and Clinical OutcomesFatehi Hassanabad, Ali MSc, MD; McBride, Susan A. MSc, MDAmerican Journal of Clinical Oncology: September 2019 - Volume 42 - Issue 9 - p 732–736 doi: 10.1097/COC.0000000000000579 Review Articles Buy Abstract Author InformationAuthors Article MetricsMetrics Lung cancer is the most common cancer worldwide. It also has the highest malignancy-associated mortality rate. Treatment options are limited by cancer and tumor heterogeneity, resistance to treatment options, and an advanced stage at time of diagnosis, all of which are common. Statins are a class of lipid-lowering medications that have been studied for their antitumor effects in various types of cancers. Multiple mechanisms have been proposed to explain their observed off-target effects. Most of these hypotheses focus largely on statin-induced upregulation of proapoptotic signaling pathways and mediators, and the downregulation of antineoplastic factors secondary to statin use. Preclinical and clinical studies support their use for conferring a mortality benefit and improving treatment effect in some chemotherapy-resistant subtypes of lung cancer. However, their exact mechanism of action, class-dependent effect, dose-dependent effect, potential use as adjuvant chemotherapeutics, and markers of statin-sensitivity in specific lung cancer subtypes remain areas of ongoing investigation. Herein, we review the latest literature pertinent to the role statins can play in the management of lung cancers. Cumming School of Medicine, University of Calgary, Calgary, AB, Canada The authors declare no conflicts of interest. Reprints: Ali Fatehi Hassanabad, MSc, MD, Room 880, Main Building 1403 29th Street NW Foothills Medical Centre Cumming School of Medicine, University of Calgary, Calgary, AB, Canada T2N 2T9. E-mail: email@example.com. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.